10-K Filing

Oruka Therapeutics, Inc. CIK: 907654 FY 2014

Filing Information

Form Type	10-K
Accession Number	`0001564590-15-001840`
Period End Date	20141231
Filing Date	20150319
Fiscal Year	2014
Fiscal Period	FY
XBRL Instance	abio-20141231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 56 Income Statement 21 Cash Flow Statement 42 Stockholders Equity 19

Balance Sheet 56 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.92M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$169.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$134.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.49M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$16.93M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$36.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$29.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$608.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$130.00K	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Total assets	`Assets`	$16.13M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Total assets	`Assets`	$17.08M	USD	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$597.00K	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$795.00K	USD	Point-in-time
Preferred stock, outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$329.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$459.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$446.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$264.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.39M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	21.15M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.50M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	15.69M	shares	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.00K	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$3.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	15.69M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	21.15M	shares	Point-in-time
Total liabilities	`Liabilities`	$1.39M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.50M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding. Series A convertible preferred stock, $0.001 par value; 135,000 shares designated from authorized preferred stock; no shares issued or outstanding at December 31, 2014 and 2013	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding. Series A convertible preferred stock, $0.001 par value; 135,000 shares designated from authorized preferred stock; no shares issued or outstanding at December 31, 2014 and 2013	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2014 and 2013; 21,150,486 and 15,685,562 shares issued and outstanding at December 31, 2014 and 2013, respectively	`CommonStockValue`	$16.00K	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2014 and 2013; 21,150,486 and 15,685,562 shares issued and outstanding at December 31, 2014 and 2013, respectively	`CommonStockValue`	$21.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$90.50M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$99.34M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-74.93M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-84.62M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$14.74M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$2.91M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$15.58M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$17.08M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$16.13M	USD	Point-in-time

Income Statement 21 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$2.93M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$5.62M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.01M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.07M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$9.69M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$6.94M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-9.69M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-6.94M	USD	Annual
Interest and other income	`InterestAndOtherIncome`	$7.00K	USD	Annual
Interest and other income	`InterestAndOtherIncome`	$5.00K	USD	Annual
Interest expense	`InterestExpense`	$4.00K	USD	Annual
Interest expense	`InterestExpense`	$3.00K	USD	Annual
Net loss and comprehensive loss	`NetIncomeLoss`	$-6.94M	USD	Annual
Net loss and comprehensive loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Less: Deemed preferred stock dividend	`PreferredStockDividendsAndOtherAdjustments`	$2.03M	USD	Annual
Net loss available to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-9.69M	USD	Annual
Net loss available to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-8.96M	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.04	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.47	USD	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	20.50M	shares	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	8.63M	shares	Annual

Cash Flow Statement 42 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-6.94M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Depreciation	`DepreciationAndAmortization`	$12.00K	USD	Annual
Depreciation	`DepreciationAndAmortization`	$26.00K	USD	Annual
Amortization of deferred charges	`AmortizationOfDeferredCharges`	$67.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$283.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$647.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-130.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-214.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$545.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-14.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$198.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$532.00K	USD	Annual
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$356.00K	USD	Annual
Accrued compensation and employee benefits	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-130.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$325.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities`	$-182.00K	USD	Annual
Other	`IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet`	$15.00K	USD	Annual
Other	`IncreaseDecreaseInOtherCurrentAssetsAndLiabilitiesNet`	$-2.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-9.41M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-5.29M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$19.00K	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$32.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-32.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-19.00K	USD	Annual
Proceeds from the issuance of preferred stock	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$20.00M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$9.04M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.74M	USD	Annual
Repayment of principal on vendor finance agreement	`RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths`	$174.00K	USD	Annual
Repayment of principal on vendor finance agreement	`RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths`	$179.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$8.02M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$19.16M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.40M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$13.84M	USD	Annual
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.92M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.92M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$16.76M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$15.35M	USD	Point-in-time
Interest paid	`InterestPaid`	$3.00K	USD	Annual
Interest paid	`InterestPaid`	$3.00K	USD	Annual

Stockholders Equity 19 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, value	`StockholdersEquity`	$14.74M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$2.91M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$15.58M	USD	Point-in-time
Issuance of common stock for cash, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$1.42M	USD	Annual
Issuance of common stock for cash, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$7.87M	USD	Annual
Issuance of common stock upon exercise of warrants for cash, value	`IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue`	$12.00K	USD	Annual
Issuance of common stock upon exercise of warrants for cash, value	`IssuanceOfCommonStockUponExerciseOfWarrantsForCashValue`	$338.00K	USD	Annual
Issuance of Series A convertible preferred stock, net of offering costs	`PreferredStockIssuedDuringPeriodValueNewIssues`	$17.92M	USD	Annual
Deemed preferred stock dividend for beneficial conversion feature	`DeemedDividendBeneficialConversionPreferredStock`	$2.03M	USD	Annual
Less: Deemed preferred stock dividend	`PreferredStockDividendsAndOtherAdjustments`	$2.03M	USD	Annual
Conversion of preferred stock	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$-20.00K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$283.00K	USD	Annual
Share-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$647.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-6.94M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.69M	USD	Annual
Ending Balance, value	`StockholdersEquity`	$14.74M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$2.91M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$15.58M	USD	Point-in-time
Issuance of common stock upon vesting of Restricted Stock Awards, value	`StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures`	$-2.00K	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.